Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Protalix BioTherapeutics Inc News

    1,14 $ -3,39% -0,04 $
    In : 1,066 € | 19:19:47 Uhr AMEX aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A2PWSL
    ISIN: US74365A3095
    US-Symbol: PLX
    Typ: Aktie

    Protalix BioTherapeutics Inc News

    14.03.24 - PR Newswire
    Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results
    Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results PR Newswire
    07.03.24 - PR Newswire
    Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024
    Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024 PR Newswire
    23.02.24 - PR Newswire
    Protalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference
    Protalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference PR Newswire
    26.12.23 - PR Newswire
    Protalix BioTherapeutics Issues 2024 Letter to Stockholders
    Protalix BioTherapeutics Issues 2024 Letter to Stockholders PR Newswire
    06.11.23 - PR Newswire
    Protalix BioTherapeutics Reports Third Quarter 2023 Financial and Business Results
    Protalix BioTherapeutics Reports Third Quarter 2023 Financial and Business Results PR Newswire
    30.10.23 - PR Newswire
    Protalix BioTherapeutics to Announce Third Quarter 2023 Financial and Business Results on November 6, 2023
    Protalix BioTherapeutics to Announce Third Quarter 2023 Financial and Business Results on November 6, 2023 PR Newswire
    09.10.23 - PR Newswire
    Protalix BioTherapeutics Issues Statement Regarding Security Situation in Israel
    Protalix BioTherapeutics Issues Statement Regarding Security Situation in Israel PR Newswire
    12.09.23 - PR Newswire
    Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors
    Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors PR Newswire
    06.09.23 - PR Newswire
    Protalix BioTherapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
    Protalix BioTherapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference PR Newswire
    07.08.23 - PR Newswire
    Protalix BioTherapeutics Reports Second Quarter 2023 Financial and Business Results
    Protalix BioTherapeutics Reports Second Quarter 2023 Financial and Business Results PR Newswire
    01.08.23 - PR Newswire
    Protalix BioTherapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
    Protalix BioTherapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference PR Newswire
    31.07.23 - PR Newswire
    Protalix BioTherapeutics to Announce Second Quarter 2023 Financial and Business Results on August 7, 2023
    Protalix BioTherapeutics to Announce Second Quarter 2023 Financial and Business Results on August 7, 2023 PR Newswire
    08.06.23 - PR Newswire
    Protalix BioTherapeutics to Host In-Person KOL Breakfast following the Approval of Elfabrio® in both the United States and the European Union for Adults with Fabry Disease
    Protalix BioTherapeutics to Host In-Person KOL Breakfast following the Approval of Elfabrio® in both the United States and the European Union for Adults with Fabry Disease PR ...
    30.05.23 - PR Newswire
    Protalix BioTherapeutics Issues Letter to Stockholders
    Protalix BioTherapeutics Issues Letter to Stockholders PR Newswire
    23.05.23 - PR Newswire
    Protalix BioTherapeutics set to join Russell 3000® Index
    Protalix BioTherapeutics set to join Russell 3000® Index PR Newswire
    18.05.23 - PR Newswire
    Protalix BioTherapeutics Announces $20 Million Milestone Payment from Chiesi Global Rare Diseases
    Protalix BioTherapeutics Announces $20 Million Milestone Payment from Chiesi Global Rare Diseases PR Newswire
    10.05.23 - PR Newswire
    Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce FDA Approval of ELFABRIO® (pegunigalsidase alfa-iwxj) for the Treatment of Fabry Disease
    Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce FDA Approval of ELFABRIO® (pegunigalsidase alfa-iwxj) for the Treatment of Fabry Disease PR Newswire
    05.05.23 - PR Newswire
    Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
    Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease ...
    04.05.23 - PR Newswire
    Thinking about buying stock in Zillow, Li Auto, Endeavour Silver, Protalix Biotherapeutics, or Oramed Pharmaceuticals?
    Thinking about buying stock in Zillow, Li Auto, Endeavour Silver, Protalix Biotherapeutics, or Oramed Pharmaceuticals? PR Newswire
    04.05.23 - PR Newswire
    Protalix BioTherapeutics Reports First Quarter 2023 Financial and Business Results
    Protalix BioTherapeutics Reports First Quarter 2023 Financial and Business Results PR Newswire

    Newssuche

    Videos

    08:40 Uhr +6,31%
    Technical Trading: Gold Long freitags
    Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »